Bio-Techne will pay $250 million in cash, as well as up to an additional $325 million contingent on the achievement of certain milestones.
One firm, Exosome Diagnostics, is working to streamline payor coverage for a commercial test, and researchers are simultaneously developing promising ways to isolate exosomes.
The collaboration among the National Cancer Center Japan, JVCKENWOOD, Sysmex, and Daiichi Sankyo aims to detect cancer-specific exosomes from patients' blood.
The funds will support a variety of business activities including diagnostic test development and the advance of new methods for tissue-specific exosome isolation.
The Swiss biopharmaceutical company said it undertook both deals to develop new therapeutic and diagnostic applications based around exosomes.